Preclinical data showed that LP-184 shrunk tumors in vivo by more than 90% in just 8 weeks.
Igor Astsaturov, MD, PhD
Advertisement
Articles by Igor Astsaturov, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
How Subcutaneous Isatuximab Could Compete With Daratumumab in Multiple Myeloma
2
FDA Approves SimpleScreen CRC Blood Test for Colorectal Cancer Screening
3
Beyond Off-Label: How Auvelity's Approval Changes Agitation Management in Alzheimer Disease
4
What Does the FDA Advisory Committee’s Vote on 7 Peptides Mean for Pharmacy Practice?
5